YD Bio Ltd Form 6-K Summary
Business Context and Reporting Period
This Form 6-K is a report of a foreign private issuer filed by YD Bio Limited for the month of September 2025. The registrant is headquartered in Taipei City, Taiwan, and files annual reports under Form 20-F. The filing includes unaudited interim financial statements and management discussion for YD Bio Limited, YD Biopharma Limited, and Breeze Holdings Acquisition Corp., along with pro forma combined financial information.
Key Financial Metrics
The provided text contains only the cover page and exhibit index of the Form 6-K. It does not include the actual financial statements or management discussion text. Consequently, specific values for revenue, profit, cash flow, margins, debt, and liquidity are not present in the source data.
Material Changes
The filing text does not provide a clear value or description of material changes versus the prior comparable period. The detailed analysis of operational results is contained in the referenced exhibits (99.1 through 99.6), which are not included in the input content.
Guidance, Outlook, and Risks
No guidance, outlook, management commentary, risks, contingencies, or unusual items are detailed in the provided text. The filing references a press release dated September 30, 2025 (Exhibit 99.7), but the content of that release is not included.
Investor Verification Checklist
- Verify the unaudited interim financial statements in Exhibits 99.1, 99.2, and 99.4 for actual revenue and cash flow figures.
- Review Exhibit 99.3 and 99.5 for management's discussion of financial condition and results of operations.
- Examine Exhibit 99.6 for pro forma condensed combined financial information regarding the business combination.
- Read the full text of the September 30, 2025 press release (Exhibit 99.7) for material updates or strategic announcements.